Meibomain Gland Dysfunction
Conditions
Interventions
Study eye:Intense pulsed light and meibomian gland massage
Control eye:meibomian gland massage
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
23 Years to 86 Years
Inclusion criteria
Inclusion criteria: 1. aged above 18 years; 2. obstruction of meibomian gland (MG) orifices observed under slit lamp examination, and meibomian gland yielding secreting score (MGYSS) in lower eyelid was no more than 12; 3. Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score at least 6 in both eyes; 4. Fitzpatrick skin type 1 to 4; 5. To be able to and willing to accept the visit of patients.
Exclusion criteria
Exclusion criteria: 1. Patients undergoing ocular surgery (including intraocular, ophthalmic, corneal or refractive surgery, lacrimal punctures insertion) or trauma during the first 6 months of baseline examination. 2. Patients with a history of intraocular inflammation (eg, retinitis, pigmentitis, scleritis, keratitis) within the first 6 months of baseline. 3 eye and appendages have microbial infection in patients. 4. Patients with eye irritation. 5. eyelid abnormalities (such as the eyelid varus, eyelid ectropion, tumor, edema, blepharospasm, eyelid closure insufficiency, trichiasis, ptosis, eyelid skin relaxation, etc.) patients. 6. moderate to severe ocular surface abnormalities (such as the history of chemical burns, recurrent corneal epithelial erosion, corneal fluorescein staining and above 3, epithelial or pre-elastic layer of malnutrition, etc.) patients. 7. Systemic diseases leading to dry eye, for example, stevens-Johnson syndrome, vitamin A deficiency, rheumatoid arthritis, Wegener's granulomatosis, sarcoidosis, leukemia, systemic lupus erythematosus, Sjogren's syndrome . ?8. Disapproximation or inability to discontinue use of a drug known to cause dry eye (eg, antihistamines) for at least one month prior to baseline examination. 9. Patients currently using lacrimal puncta embolization. 10. Patients with Fitzpatrick skin types 5, 6 or patients who had tan or tan in the 4 weeks prior to treatment. Because the skin is too high melanin density may be due to OPT effect caused by skin pigment change. At the same time, dark skin absorb more energy, may cause unsafe heating of the skin is too high. 11. Patients with nerve palsy in the pretreatment area within six months prior to the baseline examination. 12. Pre-treatment of patients with skin cancer or pigmented lesions. 13. Patients with recurrent herpes, systemic lupus erythematosus, purpura, and light that may be re-excited by light of wavelengths from 560 nm to 1200 nm. 14. Any patient who may be affected by OPT treatment of skin diseases. 15. Patients with systemic infection or immunosuppressive disease. 16. Patients who had received radiation therapy in the head and neck for the past year or who were scheduled to undergo radiotherapy within eight weeks of OPT. 17. Patients who received chemotherapy eight weeks prior to OPT or who were scheduled to receive chemotherapy within eight weeks of OPT. 18. Also participate in other ophthalmic drugs or clinical trials of patients with medical equipment. 19. pregnancy, breast-feeding patients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| meibomian gland assessment; | — |
Secondary
| Measure | Time frame |
|---|---|
| tear break-up time;standard patient evaluation of eye dryness2;corneal fluorescein staining;meibomian gland assessment; | — |
Countries
China
Contacts
Public ContactXiaoming Yan
Peking University First Hospital
Outcome results
None listed